{Reference Type}: Journal Article
{Title}: PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database.
{Author}: Ren X;Sun P;Wang Y;
{Journal}: Expert Opin Drug Saf
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 8
{Factor}: 4.011
{DOI}: 10.1080/14740338.2024.2376690
{Abstract}: <B>UNASSIGNED: </B>Current clinical trial data on PARP inhibitors (PARPis)-related acute renal failure (ARF) are not entirely representative of real-world situations. Therefore, in this study, the US Food and Drug Administration Adverse Event Reporting System (FAERS) was used to evaluate PARPis-related ARF.<BR><B>UNASSIGNED: </B>Data were obtained from 1 January 2015, to 30 September 2023. ARF event reports were analyzed based on four algorithms. The time-to-onset (TTO) and clinical outcomes of PARPis-associated ARF were assessed.<BR><B>UNASSIGNED: </B>The total included cases were 2726. Significant signals were observed for olaparib, niraparib, and rucaparib (reporting odds ratio (ROR): 1.62, 95% confidence interval (CI): 1.49-1.78, 1.25, 95% CI: 1.19-1.32 and 1.59, 95% CI: 1.47-1.72 respectively). The median TTO of ARF onset was 57, 36, and 85 days for olaparib, niraparib, and rucaparib, respectively. The proportion of deaths with olaparib (9.88%) was significantly higher than for niraparib (2.52%) and rucaparib (2.94%) (p < 0.005). The proportion of life-threatening adverse events associated with niraparib (4.89%) was significantly higher than for rucaparib (0.98%) (p < 0.005).<BR><B>UNASSIGNED: </B>ARF and PARPi were related, with the exception of talazoparib. More emphasis should be given to PARPis-related ARF due to the high proportion of serious AEs and delayed adverse reactions.